|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:cutaneous_squamous_cell_carcinoma
gptkb:FDA
basal cell carcinoma
|
|
gptkbp:ATCCode
|
L01FF05
|
|
gptkbp:CASNumber
|
1629038-50-8
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:cemiplimab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Libtayo
|
|
gptkbp:indication
|
advanced basal cell carcinoma
advanced cutaneous squamous cell carcinoma
advanced non-small cell lung cancer
locally advanced cutaneous squamous cell carcinoma
metastatic cutaneous squamous cell carcinoma
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PD-1 inhibitor
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:IgG4
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.libtayo.com/
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
gptkb:DB14081
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
rash
immune-mediated adverse reactions
|
|
gptkbp:target
|
gptkb:PD-1
|
|
gptkbp:UNII
|
4Y2S6K74RQ
|
|
gptkbp:bfsParent
|
gptkb:Regeneron
gptkb:赛诺菲
|
|
gptkbp:bfsLayer
|
6
|